Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Patient Access

STAT Pharmalot: Drug Makers Fund More Compassionate Use Programs Than You May Think

Boston, MA, August 4, 2017 — Pharmalot ‘s Ed Silverman reports on STAT News that patient advocates have long complained that drug and device makers do not make enough experimental medicines available, but a new study finds that the industry funds most trials that aim to get such products to patients.

Specifically, companies funded 61 percent of nearly 400 studies that make drugs or devices available to patients prior to regulatory approval, according to the analysis in BMS Research Notes. Continue reading

RWJBarnabas Health and Rutgers Announce Partnership Creating New Jersey’s Premier Academic Health Care System

New Brunswick, NJ, July 28, 2017 — RWJBarnabas Health and Rutgers University yesterday announced plans to partner and create the state’s largest academic health care system dedicated to providing high-quality patient care, leading-edge research and world-class health and medical education that will transform and advance health care in New Jersey.

Rutgers University President Robert Barchi, RWJBarnabas Health President and CEO Barry H. Ostrowsky and Rutgers Biomedical and Health Sciences Chancellor Brian Strom provided details of the new partnership outlined in a formal Letter of Intent during a ceremony at the Rutgers Cancer Institute of New Jersey in New Brunswick. Continue reading

Lobbying on Capitol Hill for Trumpcare, POTUS Says ‘We’re Gonna Have a Real Winner’

President Donald Trump

Washington, DC, March 21, 2017The Washington Report reports that President Trump went to Capitol Hill this morning to sell the House GOP leadership’s plan to overhaul the health-care system as the legislation races toward an expected vote on the House floor by the end of this week.

“We’re gonna have a real winner,” Trump told reporters.  “There are going to be adjustments but I think we’ll get the vote on Thursday.”

Trump predicted the legislation would pass the House after emerging from the meeting. Continue reading

PhRMA: Partnership for Prescription Assistance: 2016 in Review

Washington, DC, March 1, 2017 — More than a decade has passed since the Partnership for Prescription Assistance (PPA) launched.

In this time, PPA has helped nearly 10 million patients through its free and confidential program, but last year was a particularly special year for the program.

The PPA website added hundreds of new medicines, prescription assistance programs and free clinics to its database, which now serves an average of 75,000 visitors every month, up from 60,000 last year. Continue reading

HINJ’s ‘Value of Medical Innovation’ Portal Showcases How Life Sciences Is Saving Money — And Lives

New Brunswick, NJ, February 27, 2017 ― The HealthCare Institute of New Jersey (HINJ) continues to update its Value of Medical Innovation, a fact-driven, consumer-friendly digital library that delves into the myriad benefits of research-driven medical innovation, which saves money — and saves lives.

Introduced in September 2015, HINJ’s Value of Medical Innovation presents statistics from a number of resources, including the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Pharmaceutical Research and Manufacturers of America (PhRMA), U.S. government sources and various medical research organizations. Continue reading

Event: NJ Rare Disease Alliance Commemorates Global Rare Disease Day 2017 on February 27; Focus on Innovation, Research and Access

Glen Ridge, NJ, February 25, 2017 — The New Jersey Rare Disease Alliance, dedicated to improving the lives of the more than 800,000 rare disease patients in New Jersey, will hold its annual Rare Disease Day commemoration on Monday, February 27, at the New Jersey Business and Industry Association (NJBIA), 10 West Lafayette Street, Trenton from 9:00 AM-12:00 PM.

The event is co-sponsored by BioNJ, the HealthCare Institute of NJ (HINJ) and the National Organization for Rare Diseases (NORD). Continue reading

HINJ’s ‘Value of Medical Innovation’ Portal Showcases How Life Sciences Is Saving Money — And Lives

New Brunswick, NJ, February 18, 2017 ― The HealthCare Institute of New Jersey (HINJ) continues to update its Value of Medical Innovation, a fact-driven, consumer-friendly digital library that delves into the myriad benefits of research-driven medical innovation, which saves money — and saves lives.

HINJ’s Value of Medical Innovation presents statistics from a number of resources, including the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Pharmaceutical Research and Manufacturers of America (PhRMA), U.S. government sources and various medical research organizations. Continue reading

BIO Produces Video Explaining How Drug Costs Are Really Determined

 

Washington, DC, February 11, 2017 — Today, much of the public debate surrounding the cost of biopharmaceuticals is focused on the list price of an individual drug or treatment regimen.

However, the list price is not what a manufacturer generally makes on the drug, and it typically has little to do with what a patient has to pay for his or her medicine.

To help put this debate into context, the Biotechnology Innovation Organization (BIO) is releasing a new educational video today designed to give patients, consumers, policy makers and journalists a better understanding of how prescription drug costs are really determined and where the pharmaceutical dollar actually goes. Continue reading

Biotechnology Executives Write President, Arguing Immigration Ban Strikes at U.S. Medical Innovation and Patients

Washington, DC, February 9, 2017 — Carolyn Y. Johnson reports in The Washington Post that more than 160 leaders of biotechnology companies signed a strong letter of opposition to President Donald J. Trump’s travel ban, arguing the “poorly conceived and implemented” action strikes at the heart of an industry that originated in America, has been dominated by American companies and is at the cutting edge of medicine.

The letter, published Tuesday by the journal Nature Biotechnology, reveals that scientists abroad are afraid to come to the U.S. and are canceling trips.

Foreign-born scientists within the U.S. fear similar orders could be issued without warning, and some have expressed anxiety about deportation or losing family ties.  Ultimately, the letter argues, the policy will harm patients and the U.S. economy. Continue reading

Drugmakers Announce $50 Million Investment to Fight Chronic Diseases in Poor Countries

Lab 3 VerticalDavos, Switzerland, January 19, 2017 — Reuters reports that two decades after they were spurred into action to tackle AIDS in Africa, global drugmakers said yesterday that they would invest an initial $50 million over three years to fight cancer and other non-communicable diseases in poor countries.

Twenty-two companies — including Pfizer, Merck, Novartis, Roche, Sanofi and GlaxoSmithKline — will contribute funds and expertise to the project, which is backed by the World Bank. Continue reading